Colitis and hypophysitis often occur in patients receiving CTLA4 inhibitors, while less common AEs (pneumonitis and thyroiditis) may occur in patients using drugs targeting PD-1/PD-L1 pathway (271, 277, 278). Here, CTLA4 is linked to thyroid gland disorder.